(Q39265240)

English

Optimizing dendritic cell vaccine for immunotherapy in multiple myeloma: tumour lysates are more potent tumour antigens than idiotype protein to promote anti-tumour immunity

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

10 September 2017

Optimizing dendritic cell vaccine for immunotherapy in multiple myeloma: tumour lysates are more potent tumour antigens than idiotype protein to promote anti-tumour immunity (English)

1 reference

Europe PubMed Central

10 September 2017

1 reference

based on heuristic

inferred from title

multiple myeloma

1 reference

based on heuristic

inferred from title

author name string

S Hong

1

1 reference

Europe PubMed Central

10 September 2017

H Li

2

1 reference

Europe PubMed Central

10 September 2017

J Qian

3

1 reference

Europe PubMed Central

10 September 2017

J Yang

4

1 reference

Europe PubMed Central

10 September 2017

Y Lu

5

1 reference

Europe PubMed Central

10 September 2017

Q Yi

6

1 reference

Europe PubMed Central

10 September 2017

publication date

1 November 2012

1 reference

Europe PubMed Central

10 September 2017

Clinical and Experimental Immunology

1 reference

Europe PubMed Central

10 September 2017

170

1 reference

Europe PubMed Central

10 September 2017

167-177

1 reference

Europe PubMed Central

10 September 2017

2

1 reference

Europe PubMed Central

10 September 2017

Optimizing dendritic cell-based immunotherapy in multiple myeloma: intranodal injections of idiotype-pulsed CD40 ligand-matured vaccines led to induction of type-1 and cytotoxic T-cell immune responses in patients

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3482363

30 August 2018

Novel immunotherapies

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3482363

30 August 2018

Vaccines for lymphomas: idiotype vaccines and beyond

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3482363

30 August 2018

Roles of idiotype-specific t cells in myeloma cell growth and survival: Th1 and CTL cells are tumoricidal while Th2 cells promote tumor growth

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3482363

30 August 2018

Multiple myeloma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3482363

30 August 2018

Dickkopf-1 (DKK1) is a widely expressed and potent tumor-associated antigen in multiple myeloma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3482363

30 August 2018

Dendritic cell vaccine but not idiotype-KLH protein vaccine primes therapeutic tumor-specific immunity against multiple myeloma.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3482363

30 August 2018

Preclinical development of hybrid cell vaccines for multiple myeloma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3482363

30 August 2018

Targeting heat shock proteins for immunotherapy in multiple myeloma: generation of myeloma-specific CTLs using dendritic cells pulsed with tumor-derived gp96.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3482363

30 August 2018

Allogeneic dendritic cells pulsed with tumor lysates or apoptotic bodies as immunotherapy for patients with early-stage B-cell chronic lymphocytic leukemia.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3482363

30 August 2018

Enhanced antitumor immunity derived from a novel vaccine of fusion hybrid between dendritic and engineered myeloma cells

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3482363

30 August 2018

Cancer immunotherapy: moving beyond current vaccines

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3482363

30 August 2018

Immunotherapy in multiple myeloma: current strategies and future prospects

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3482363

30 August 2018

Vaccination of patients with cutaneous T-cell lymphoma using intranodal injection of autologous tumor-lysate–pulsed dendritic cells

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3482363

30 August 2018

Immunotherapy of metastatic renal cell carcinoma with tumor lysate-pulsed autologous dendritic cells.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3482363

30 August 2018

The 5TMM series: a useful in vivo mouse model of human multiple myeloma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3482363

30 August 2018

Active immunization against cancer with dendritic cells: the near future

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3482363

30 August 2018

Preclinical models of bone metastases

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3482363

30 August 2018

Idiotype vaccination using dendritic cells after autologous peripheral blood progenitor cell transplantation for multiple myeloma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3482363

30 August 2018

An advanced culture method for generating large quantities of highly pure dendritic cells from mouse bone marrow

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3482363

30 August 2018

Dendritic cells and the control of immunity

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3482363

30 August 2018

A murine model of human myeloma bone disease

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3482363

30 August 2018

Dendritic cells hold promise for immunotherapy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3482363

30 August 2018

Vaccination with syngeneic, lymphoma-derived immunoglobulin idiotype combined with granulocyte/macrophage colony-stimulating factor primes mice for a protective T-cell response

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3482363

30 August 2018

Dendritic cells as adjuvants for class I major histocompatibility complex-restricted antitumor immunity

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3482363

30 August 2018

Tumor antigens recognized by T lymphocytes

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3482363

30 August 2018

Dendritic cells as initiators of tumor immune responses: a possible strategy for tumor immunotherapy?

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3482363

30 August 2018

Idiopathic paraproteinemia. II. Transplantation of the paraprotein-producing clone from old to young C57BL/KaLwRij mice

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3482363

30 August 2018

Multiple Myeloma

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2249.2012.04642.X

21 January 2018

Phase I/II clinical trial of sequential subcutaneous and intravenous delivery of dendritic cell vaccination for refractory multiple myeloma using patient-specific tumour idiotype protein or idiotype (VDJ)-derived class I-restricted peptides

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2249.2012.04642.X

21 January 2018

Tumour cell/dendritic cell fusions as a vaccination strategy for multiple myeloma

1 reference

https://pubmed.ncbi.nlm.nih.gov/23039887

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Idiotype-specific cytotoxic T lymphocytes in multiple myeloma: evidence for their capacity to lyse autologous primary tumor cells

1 reference

https://pubmed.ncbi.nlm.nih.gov/23039887

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Deletion of idiotype (Id)-specific T cells in multiple myeloma

1 reference

https://pubmed.ncbi.nlm.nih.gov/23039887

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Tumor lysate-specific cytotoxic T lymphocytes in multiple myeloma: promising effector cells for immunotherapy

1 reference

https://pubmed.ncbi.nlm.nih.gov/23039887

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Optimizing dendritic cell-based immunotherapy in multiple myeloma

1 reference

https://pubmed.ncbi.nlm.nih.gov/23039887

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells

1 reference

https://pubmed.ncbi.nlm.nih.gov/23039887

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Vaccination of multiple myeloma patients with idiotype-pulsed dendritic cells: immunological and clinical aspects

1 reference

https://pubmed.ncbi.nlm.nih.gov/23039887

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1111/J.1365-2249.2012.04642.X

1 reference

Europe PubMed Central

10 September 2017

0 references

1 reference

Europe PubMed Central

10 September 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q39265240&oldid=1817328526"